Jump to content

DFL23916

From Wikipedia, the free encyclopedia

DFL23916
Identifiers
  • 7-[3-[(4-fluoro-2-methyl-5-phenylphenyl)sulfamoyl]phenyl]heptanoic acid
PubChem CID
Chemical and physical data
FormulaC26H28FNO4S
Molar mass469.57 g·mol−1
3D model (JSmol)
  • CC1=CC(=C(C=C1NS(=O)(=O)C2=CC=CC(=C2)CCCCCCC(=O)O)C3=CC=CC=C3)F
  • InChI=1S/C26H28FNO4S/c1-19-16-24(27)23(21-12-6-4-7-13-21)18-25(19)28-33(31,32)22-14-9-11-20(17-22)10-5-2-3-8-15-26(29)30/h4,6-7,9,11-14,16-18,28H,2-3,5,8,10,15H2,1H3,(H,29,30)
  • Key:VDGLRVBSCZCZGY-UHFFFAOYSA-N

DFL23916 is an experimental drug which acts as a mixed agonist for the free fatty acid receptors FFAR1 (GPR40) and FFAR4 (GPR120). Unlike the older drug GW9508 which is selective for FFAR1, DFL23916 has a balanced efficacy at both receptor targets. It increases GLP-1 secretion and improved glucose homeostasis in mice.[1][2]

References

[edit]
  1. ^ Bianchini G, Nigro C, Sirico A, Novelli R, Prevenzano I, Miele C, et al. (July 2021). "A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 139: 111613. doi:10.1016/j.biopha.2021.111613. PMID 33895521.
  2. ^ Brunetti K, Catalani E, Del Quondam S, Romano N, Ceci M, Clerici G, et al. (June 2025). "A novel free fatty acid receptor agonist improving metabolic health in Drosophila models". Pharmacological Research. 216: 107769. doi:10.1016/j.phrs.2025.107769. PMID 40348099.